Table 1 Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or trogliazone.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  | Placebo group | Troglitazone group | P |
| n | 122 | 114 |  |
| Clinical Characteristics |  |   |  |
|  Age (years) | 34.3±6.5 | 34.9±6.6 | 0.52 |
|  BMI (kg | 30.3±5.3 | 30.6±6.1 | 0.63 |
|  Waist-to-hip circumference ratio  | 0.86±0.05 | 0.85±0.06 | 0.19 |
|  Using hormonal contraceptives \*  | 48% | 43% | 0.41 |
| OGTT ƚ |  |  |  |
|  Fasting Glucose (mg/dl) | 98.1±9.1 | 98.7±10.2 | 0.64 |
| 2-h glucose  Total glucose area  | 15.40±24.0 | 154.4±27.0 | 0.97 |
|  (mg/dl x min x 10-3) ï | 18.7±9.7 | 18.9±2.0 | 0.25 |
|  Impaired glucose tolerance©  | 72% | 69% | 0.66 |
|  Fasting Insulin (µU/ml)  | 16.0 | 17.0±10.8 | 0.82 |
|  Total insulin area (µU/ml x min) ï  | 10,209±5536 | 9,902±6543 | 0.55 |
|  |  |  |  |
|  |  |  |  |